Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER
Posted inCardiology news

Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER

A multicountry, single‑arm pivotal trial of the SAPIEN M3 transseptal transcatheter mitral valve replacement (TMVR) in patients deemed unsuitable for surgery or TEER demonstrated a 1‑year composite rate of death or heart‑failure rehospitalisation of 25.2%, significantly below the prespecified 45% performance goal, with few intraprocedural complications.
Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit
Posted inCardiology General Surgery news

Liberal vs Restrictive Postoperative Transfusion in High-Cardiac-Risk Surgery: TOP Trial Shows No Mortality or Major Ischemic Benefit

In high–cardiac-risk veterans after major vascular or general surgery, a liberal postoperative transfusion threshold (Hb <10 g/dL) did not reduce 90‑day death or major ischemic events compared with a restrictive threshold (Hb <7 g/dL); some non‑MI cardiac complications were less frequent with liberal transfusion.
Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial
Posted inCardiology news

Daily Caffeinated Coffee After Cardioversion Cuts Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

The DECAF randomized trial found that encouraging caffeinated coffee consumption (≈1 cup/day) after successful cardioversion reduced clinically detected AF/flutter recurrence over 6 months versus caffeine abstinence (47% vs 64%; HR 0.61). Results challenge routine caffeine restriction in AF patients but require confirmation and contextualization.
Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results
Posted inCardiology Gastroenterology news

Olezarsen Significantly Lowers Triglycerides and Cuts Pancreatitis Risk in Severe Hypertriglyceridemia: CORE‑TIMI 72a/CORE2‑TIMI 72b Results

Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher doses were linked to liver enzyme elevations, thrombocytopenia, and increased hepatic fat.
Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin
Posted inCardiology Neurology news

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while numerically more major bleeding occurred with rivaroxaban.
First-in-Human CRISPR-Cas9 Editing of ANGPTL3 Shows Dose‑Dependent Protein Knockdown with Acceptable Short‑Term Safety in Phase 1 Trial
Posted inCardiology news

First-in-Human CRISPR-Cas9 Editing of ANGPTL3 Shows Dose‑Dependent Protein Knockdown with Acceptable Short‑Term Safety in Phase 1 Trial

A phase 1, ascending‑dose study of CTX310 (LNP-delivered CRISPR-Cas9 targeting ANGPTL3) in 15 patients produced dose-dependent ANGPTL3 reductions at ≥0.6 mg/kg with few acute safety signals; longer follow‑up and larger trials are required to define efficacy, durability, and long-term risks.
No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials
Posted inCardiology news

No Routine Benefit from Beta‑Blockers After Myocardial Infarction with Preserved Ejection Fraction: Individual‑Patient Meta‑analysis of Five Randomized Trials

An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indications for beta blockade.
GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Posted inCardiology Diabetes & Endocrinology news

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults and those with ASCVD, HF, or kidney impairment.